Brief: Hansa Biopharma Announces Positive Reimbursement Decision In Spain For Idefirix As Desensitization Treatment
29/03/2023 16:12
March 29 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES POSITIVE REIMBURSEMENT DECISION
IN
SPAIN FOR IDEFIRIX® (IMLIFIDASE) AS DESENSITIZATION TREATMENT
FOR HIGHLY SENSITIZED PATIENTS IN KIDNEY TRANSPLANTATION
Source text for Eikon: ID:nPn3pn7Zka
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS